GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO 주식 보고서

시가총액: ₹451.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

GlaxoSmithKline Pharmaceuticals 미래 성장

Future 기준 확인 5/6

GlaxoSmithKline Pharmaceuticals (는) 각각 연간 25.4% 및 10.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 18.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 39.1% 로 예상됩니다.

주요 정보

25.4%

수익 성장률

18.8%

EPS 성장률

Pharmaceuticals 수익 성장18.5%
매출 성장률10.2%
향후 자기자본 수익률39.1%
애널리스트 커버리지

Low

마지막 업데이트10 Oct 2024

최근 미래 성장 업데이트

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Recent updates

We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

Aug 29
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease

The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 05
The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

Jun 01
Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%

With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

May 05
With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Jul 07
Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

수익 및 매출 성장 예측

NSEI:GLAXO - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
3/31/202641,90610,11610,219N/A3
3/31/202537,5598,5387,526N/A4
6/30/202435,0676,400N/AN/AN/A
3/31/202434,5375,9005,5085,820N/A
12/31/202333,1145,289N/AN/AN/A
9/30/202333,0846,4786,4496,890N/A
6/30/202332,6836,237N/AN/AN/A
3/31/202332,5176,0764,4024,842N/A
12/31/202232,7394,195N/AN/AN/A
9/30/202232,8753,9403,7864,133N/A
6/30/202233,0483,897N/AN/AN/A
3/31/202232,7803,8087,7618,107N/A
12/31/202134,8615,100N/AN/AN/A
9/30/202134,7084,9627,9128,354N/A
6/30/202133,4033,684N/AN/AN/A
3/31/202129,2562,8735,3375,779N/A
12/31/202031,6094,819N/AN/AN/A
9/30/202030,823-3,3583,8605,419N/A
6/30/202030,850905N/AN/AN/A
3/31/202032,2449323,3464,905N/A
12/31/201931,9941,019N/AN/AN/A
9/30/201932,4618,7682,8455,758N/A
6/30/201931,8044,749N/AN/AN/A
3/31/201931,2814,4541,1824,095N/A
3/31/201828,7153,507N/A4,728N/A
3/31/201729,0853,368N/A2,344N/A
3/31/201628,3793,761N/A1,389N/A
3/31/201526,3843,811N/A2,701N/A
12/31/201325,5974,817N/A2,813N/A

애널리스트 미래 성장 예측

수입 대 저축률: GLAXO 의 연간 예상 수익 증가율( 21.8% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: GLAXO 의 연간 수익( 21.8% ) Indian 시장( 15.9% 보다 빠르게 성장할 것으로 예상됩니다. 15.9% 연간).

고성장 수익: GLAXO 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: GLAXO 의 수익(연간 10.2% ) Indian 시장( 10.1% 보다 빠르게 성장할 것으로 예상됩니다. 10.1% 연간).

고성장 수익: GLAXO 의 수익(연간 9.5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: GLAXO 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 39.1 %)


성장 기업 발견